Chronic Lymphocytic Leukemia
Duvelisib, a first-in-class dual inhibitor of PI3K-delta and -gamma, was evaluated in patients with relapsed/refractory CLL/SLL and in patients with refractory indolent non-Hodgkin lymphoma.
A group of Australian researchers report study findings that demonstrate a significant improvement in PFS in patients with relapsed/refractory CLL treated with venetoclax plus rituximab compared with the standard care.
Venetoclax plus rituximab increases progression-free survival in relapsed chronic lymphocytic leukemiaMarch 31, 2018
1. Patients with relapsed or remitting chronic lymphocytic leukemia (CLL) treated with venetoclax-rituximab had a greater 2-year progression-free survival rate compared to bendamustine-rituximab treated patients. 2. Progression-free survival rates were greater for venetoclax-rituximab patients in almost all subgroup analysis, including patients with chromosome 17p deletion. Evidence Rating Level: 1 (Excellent) Study Rundown: Curative treatment of relapsed 
Researchers used mouse cells to determine activation levels of FcγRIIIa and FcγRI using obinutuzumab, rituximab and ofatumumab.
What are key monitoring guidelines for patients with CLL being treated with venetoclax?
Investigators sought to determine the efficacy of 2-year rituximab maintenance therapy in elderly patients with CLL who achieve a complete response to abbreviated FCR induction therapy.
The efficacy and safety of venetoclax in patients with relapsed/refractory CLL that progressed during or after ibrutinib therapy was determined in an open-label, phase 2 study.
Despite its high response rate, researchers are finding that patients with endothelial activation prior to lymphodepletion chemotherapy are at greater risk of neurologic adverse events after undergoing CAR T-cell therapy for relapsed/refractory B-ALL, CLL, or NHL.
Results of this double-blind, phase 3 study reports on impact of lenalidomide maintenance therapy on risk of disease progression in patients with CLL who did not achieve minimal residual disease state after first-line chemoimmunotherapy.
Lenalidomide reduced the relative risk of disease progression in a clinical trial of patients with chronic lymphocytic leukemia who did not achieve MRD negative disease state after first-line chemoimmunotherapy.
Case study demonstrates the effectiveness of long-term treatment with an oral nonpeptide receptor agonist in a 69-year-old male patient with CLL-associated ITP.
Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic LeukemiaFebruary 15, 2017
In a study seeking new therapies to improve outcomes for patients with relapsed or refractory CLL, researchers investigated the impact on progression-free survival of adding idelalisib to bendamustine plus rituximab.
Ibrutinib appears to be superior first kinase inhibitor for individuals with chronic lymphocytic leukemia, according to a recent real-world study.
In this study, researchers evaluated whether ruxolitinib, a JAK2 inhibitor that reduces symptoms in patients with myelofibrosis, would improve disease-related symptoms in patients with CLL.
Abnormal lipid metabolism is observed in patients with CLL, prompting an investigation to determine if prevalence of metabolic syndrome is higher in patients with CLL and whether lipid-lowering medications impact survival.
Expression of ROR1 could promote leukemia-cell activation and enhance disease progression in patients with chronic lymphocytic leukemia, according to a study.
In an observational study of an independent cohort of patients with Binet stage A CLL, researchers sought to validate the ability of the CLL International Prognostic Index to predict time to first treatment (TTFT) and overall survival in patients with early-stage disease.
This fact sheet reviews the incidence and survival statistics of chronic lymphocytic leukemia.
Economic Evaluation of Obinutuzumab in Combination With Chlorambucil in First-line Treatment of Patients With Chronic Lymphocytic Leukemia in SpainSeptember 29, 2016
[ClinicoEconomics and Outcomes Research] This research examines the cost-effectiveness of obinutuzumab in combination with chlorambucil (GClb) versus rituximab plus chlorambucil (RClb) in the treatment of previously untreated chronic lymphocytic leukemia.
Assessment of minimal residual disease (MRD) improves the prediction of progression-free survival benefit in patients with CLL who achieve either a complete response or a partial response PR.
The US Food and Drug Administration has approved ofatumumab in combination with fludarabine and cyclophosphamide for the treatment of relapsed chronic lymphocytic leukemia (CLL).
Treatment with ibrutinib is associated with a high overall response rate in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and 17p deletion.
Patients with chronic lymphocytic leukemia (CLL) who discontinue TKI therapy due to toxicity can successfully be treated with an alternate TKI.
Ibrutinib treatment for chronic lymphocytic leukemia with the deletion of chromosome 17p (del17p CLL) increases the percentage of patients alive at 30 months over other therapies for del17p CLL.
New research indicates that rituximab maintenance therapy can extend progression-free survival in patients with chronic lymphocytic leukemia achieving at least a partial response to induction therapy with rituximab and chemotherapy.
Prognostic Index Will Improve Clinical Practice Management of Patients With CLL and in Clinical TrialsJune 10, 2016
An international consortium devised an international prognostic index for chronic lymphocytic leukemia (CLL-IPI) that combines genetic, biochemical, and clinical parameters into a prognostic model to enable more targeted management of patients with CLL.
The US FDA has granted Priority Review to ofatumumab used in combination with fludarabine and cyclophosphamide for the treatment of chronic lymphocytic leukemia.
Hair and nail abnormalities are commonly associated with the Bruton tyrosine kinase inhibitor ibrutinib.
Immunotherapeutic Agent Blocks Protein-Protein Interaction That Supports Chronic Lymphocytic Leukemia Growth and MetastasisJanuary 11, 2016
Wnt5a protein acts on a pair of tumor-surface proteins to accelerate the proliferation and spread of CLL. These effects of Wnt5a were blocked by a humanized monoclonal antibody called cirmtuzumab, according to a recent study.
Improvements were observed in progression-free survival, overall survival, and response rate for ibrutinib usage.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|